Ancestim
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| s.c. injection only, premedication with H1 and H2 antihistamines and beta-receptor agonists for bronchodilation | |
| Pharmacokinetic data | |
| Half-life | 2.5 h |
| Excretion | renal: 90% |
| Identifiers | |
163545-26-4  | |
| L03AA12 | |
| UNII |
PYB4Q6JG41  |
| KEGG |
D02937 |
| Chemical data | |
| (what is this?) (verify) | |
Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008.[1]
It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor.[2] It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplanation in certain cancer patients.[3]
References
- ↑ Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen
- ↑ da Silva MG, Pimentel P, Carvalhais A et al. (2004). "Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection". Bone Marrow Transplant. 34 (8): 683–91. doi:10.1038/sj.bmt.1704602. PMID 15322567.
- ↑ Sobi's StemGen page]